Audit in process? Call the number on your audit letter to get options.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
June 26, 2019 - FDA announced the discontinuation of ViiV Healthcare’s Rescriptor (delavirdine) 200 mg tablets.
Download PDF
Return to publications
